Health Care·Biotechnology·$4.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.51 | N/A | -4.07% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-1.51 | N/A | -4.07% |
| Revenue | N/A | N/A | N/A |
Tone: Defensive
Management acknowledged the challenges faced in the quarter but emphasized their commitment to ongoing research and development. They did not provide specific guidance, reflecting a cautious approach.
Management did not provide specific guidance for the upcoming quarters.
The focus remains on advancing their pipeline despite the current losses.
The earnings report indicates that CRISPR Therapeutics continues to operate at a loss, with a notable EPS miss. The stock reacted negatively, dropping 1.97%, likely due to the lack of revenue information and guidance. Investors may be concerned about the company's financial health and future direction without clear expectations.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
CADENCE DESIGN SYS I
Apr 26, 2021